Immatics Streamlines SUPRAME Trial, Reports $448M Cash and Strong ASCO Data
IMTX sits 83% above its 52-week low of $5.05 on elevated volume (2.3× avg).
Summary
Immatics reported Q2 2026 results with $448.2M in cash, runway into 2028, and a key SUPRAME trial design change: slower-than-modeled PFS events mean the company will skip the interim analysis and go straight to a single streamlined final analysis, with topline data now expected H1 2027 and BLA submission in 2027. Updated Phase 1b anzu-cel data at ASCO 2026 showed 56% cORR and 16.2 months mOS in metastatic melanoma, reinforcing the lead program's profile. The trial design change reduces near-term data catalysts but strengthens the final analysis and OS power, which the company frames as a more efficient path to approval. Watch for ESMO 2026 presentations of IMA203CD8 and IMA402 data, and the H1 2027 SUPRAME topline readout.
At the time of this announcement, IMTX was trading at $9.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.05 to $12.41. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.